Lupus Clinical Trials Unit
https://www.niams.nih.gov/labs/hasni-lab
Led by Dr. Sarfaraz Hasni, the unit studies the natural history and pathogenesis of lupus and involved in designing and conducting early phase clinical trials.
Displaying 701 - 720 of 1017 results
Nuestra misión
https://www.niams.nih.gov/node/2682
La misión del Instituto Nacional de Artritis y Enfermedades Musculoesqueléticas y de la Piel (NIAMS, por sus siglas en inglés) es apoyar las investigaciones científicas sobre las causas, los tratamientos y la prevención de la artritis y las enfermedades musculoesqueléticas y de la piel, capacitar a los científicos en investigación
Funding Patterns Fiscal Year 2018
https://www.niams.nih.gov/about/budget/fy2018/patterns
January 06, 2020 The decision to fund or not to fund a particular application is based on the assessment of scientific merit by a peer review group and on the relevance of the proposed work to the Institute's scientific and health priorities. Peer reviewers' judgments of scientific merit are expressed
Laura L. Akins
https://www.niams.nih.gov/about/directory/laura-l-akins
Laura L. Akins, Administrative Management Branch - AMB-OD
Clinical Trials in the Spotlight - Completed Recruitment
NIAMS-funded clinical trials that are no longer recruiting but remain active to complete other study activities.
FY 2021 Congressional Justification
https://www.niams.nih.gov/about/budget/fy2021/congressional-justification
FY 2021 Congressional Justification page (HTML and downloadable PDF)
Subset Analysis in Clinical Studies Roundtable - March 11, 2020
See participant list See Backgrounder Summary Welcome (Bob Carter, 0:00 1) Dr. Carter provided an overview of why NIAMS was holding this meeting (see background), acknowledged key staff who were involved in its development, and urged participants to keep the discussions focused on the scientific needs and opportunities related to subset analysis in clinical studies. He asked everyone to think broadly about how the various statistical approaches could be applied to NIAMS mission areas and to share their contributions during the afternoon discussion. 1 Times are noted in approximate hours and minutes on the videocast. The link does not take
Finger Numbness, Could It Be Carpal Tunnel Syndrome?
https://www.niams.nih.gov/finger-numbness-could-it-be-carpal-tunnel-syndrome
Resource-based Centers
The Resource–based Centers (P30) provide critical research infrastructure, shared facilities, services, and resources to groups of investigators, with the broad overall goal of accelerating, enriching, and enhancing the effectiveness of ongoing basic, translational, and clinical research and promoting new research within the NIAMS mission. The components include one or more
Core Centers for Clinical Research (CCCR)
The Core Centers for Clinical Research (CCCR) (P30) provides avenues to advance the methodological sciences that support clinical research within and across the NIAMS’ portfolio of diseases. They address existing and future research needs in musculoskeletal, rheumatologic, and skin diseases by fostering the development, implementation, and inclusion of novel data
Scientists Pinpoint Traitorous Immune Cells in Lupus
https://www.niams.nih.gov/scientists-pinpoint-traitorous-immune-cells-lupus
Scientists can distinguish between highly similar cell types using cutting-edge laboratory procedures. Using such techniques, IRP researchers have identified a particular variety of cell in a specific stage of its life cycle as a primary culprit behind the autoimmune disease known as lupus.
Colbert Selected to Lead NIAMS Clinical Research Program
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) appointed Robert A. Colbert, M.D., Ph.D., as the director of the Institute's Clinical Research Program on February 16, 2020. Colbert, who joined the NIAMS in 2008, had served as deputy clinical director since 2012 and as acting clinical director since June 2018. "What excites me about the NIAMS Clinical Research Program director position is the opportunity we have to make an impact," Colbert explained. "We have a number of research programs that are making new discoveries that reveal how diseases develop and evolve and are translating these discoveries into
NIH researchers discover gene for rare disease of excess bone tissue growth
Researchers at the National Institutes of Health have discovered a second gene that causes melorheostosis, a rare group of conditions involving an often painful and disfiguring overgrowth of bone tissue. The gene, SMAD3, is part of a pathway that regulates cell development and growth. The researchers are now working to develop an animal model with a mutant version of SMAD3 to test potential treatments for the condition. The study appears in the Journal of Experimental Medicine.